In order to further extend its biology and integrated drug discovery offering Peakdale Molecular Limited has added two new members to its team. Christopher Doe, PhD, joins as Head of Biology and Sascha Hartmann has joined the business development team as Business Development Manager – Biology Services.
Chris, who will be based at Discovery Park in Sandwich, joins the Peakdale team with extensive experience of drug discovery and pre-clinical development gained across multiple therapeutic areas. His most recent role was Head of Systems and Safety Pharmacology at Almirall, Barcelona and, prior to this, Chris has held positions at GSK and Pfizer. He will be responsible for driving the strategy and growth of the biological sciences offering and extending Peakdale’s ability to deliver fully integrated drug discovery programmes across multiple protein target classes. This forward-looking approach will ensure the services offered by Peakdale remain at the forefront of small molecule drug discovery.
Speaking about the new role Chris said: “This is a great opportunity to build on the strong heritage in medicinal and synthetic chemistry, ADME and toxicology within Concept Life Sciences, exploiting synergies across the group, enabling the development of an integrated Drug Discovery platform, which can be tailored to our customer needs.
“The aim is not only to expedite the prosecution of new drug targets, but bring the breadth and depth of scientific understanding within the Concept group to provide resolution to the inevitable challenges faced during the drug Discovery and Development process.”
Sascha joins Peakdale with nearly 20 years of experience in the Biotech and Pharma industries. After gaining his MSc in Chemistry from the University of Darmstadt, Sascha began his career as an organic chemist in the Isotope and Metabolite Synthesis laboratories at Sanofi working on isotopically labelled compounds for preclinical ADMET studies. In 2001 he joined Merck Sharp & Dohme as a Medicinal Chemist contributing to a range of discovery programs in depression and Alzheimer’s research. He then moved on to Selcia, initially as a radiochemist but soon taking on a commercial role within the Business Development function, where he helped grow the custom radiosynthesis offering from a niche to a leading player in its field.
Commenting on his new role Sascha said: “I am excited to be joining Peakdale Molecular at this time of transformation and opportunity. I have always known and respected Peakdale as one of the leading players in chemistry and drug discovery services and look forward to contributing to the company’s development within the Concept Life Sciences Group and making it even more successful.”
Peakdale, a UK-based provider of drug discovery services to the pharmaceutical and biotech market, is part of the Concept Life Sciences Group which was formed following the acquisition of Peakdale Molecular Limited, Scientific Analysis Laboratories Limited and Resource & Environmental Consultants Limited. The integrated group further expanded following the acquisition of CXR Biosciences and Agenda1 Analytical Services in 2015 and offers a comprehensive range of services to clients in the pharmaceutical, biotech, agrochemical, petrochemical, chemical, food, environmental and consumer industries. The combination of expertise housed within the Concept Life Sciences Group enables companies to access a broad range of services with one point of contact. As such Peakdale seeks to work with clients on collaborative programmes. The recruitment of a Head of Biology and a member of the business development team with specific experience in this field will enable Peakdale to offer fully integrated drug discovery programmes with medicinal chemistry informed by biological data and pro-actively market this offering to their existing and potential new customers globally.
Chris, who will be based at Discovery Park in Sandwich, joins the Peakdale team with extensive experience of drug discovery and pre-clinical development gained across multiple therapeutic areas. His most recent role was Head of Systems and Safety Pharmacology at Almirall, Barcelona and, prior to this, Chris has held positions at GSK and Pfizer. He will be responsible for driving the strategy and growth of the biological sciences offering and extending Peakdale’s ability to deliver fully integrated drug discovery programmes across multiple protein target classes. This forward-looking approach will ensure the services offered by Peakdale remain at the forefront of small molecule drug discovery.
Speaking about the new role Chris said: “This is a great opportunity to build on the strong heritage in medicinal and synthetic chemistry, ADME and toxicology within Concept Life Sciences, exploiting synergies across the group, enabling the development of an integrated Drug Discovery platform, which can be tailored to our customer needs.
“The aim is not only to expedite the prosecution of new drug targets, but bring the breadth and depth of scientific understanding within the Concept group to provide resolution to the inevitable challenges faced during the drug Discovery and Development process.”
Sascha joins Peakdale with nearly 20 years of experience in the Biotech and Pharma industries. After gaining his MSc in Chemistry from the University of Darmstadt, Sascha began his career as an organic chemist in the Isotope and Metabolite Synthesis laboratories at Sanofi working on isotopically labelled compounds for preclinical ADMET studies. In 2001 he joined Merck Sharp & Dohme as a Medicinal Chemist contributing to a range of discovery programs in depression and Alzheimer’s research. He then moved on to Selcia, initially as a radiochemist but soon taking on a commercial role within the Business Development function, where he helped grow the custom radiosynthesis offering from a niche to a leading player in its field.
Commenting on his new role Sascha said: “I am excited to be joining Peakdale Molecular at this time of transformation and opportunity. I have always known and respected Peakdale as one of the leading players in chemistry and drug discovery services and look forward to contributing to the company’s development within the Concept Life Sciences Group and making it even more successful.”
Peakdale, a UK-based provider of drug discovery services to the pharmaceutical and biotech market, is part of the Concept Life Sciences Group which was formed following the acquisition of Peakdale Molecular Limited, Scientific Analysis Laboratories Limited and Resource & Environmental Consultants Limited. The integrated group further expanded following the acquisition of CXR Biosciences and Agenda1 Analytical Services in 2015 and offers a comprehensive range of services to clients in the pharmaceutical, biotech, agrochemical, petrochemical, chemical, food, environmental and consumer industries. The combination of expertise housed within the Concept Life Sciences Group enables companies to access a broad range of services with one point of contact. As such Peakdale seeks to work with clients on collaborative programmes. The recruitment of a Head of Biology and a member of the business development team with specific experience in this field will enable Peakdale to offer fully integrated drug discovery programmes with medicinal chemistry informed by biological data and pro-actively market this offering to their existing and potential new customers globally.
